CDC Investigators of Enteric Fever Favor Tailored Treatment

CDC investigators are recommending tailored antibiotic treatments for enteric fever due to rising antimicrobial resistance in the United States. The study highlights that many cases are linked to international travel and show resistance to standard first-line medications.
Why it matters
The rise of drug-resistant typhoid strains poses a significant public health challenge, necessitating updated clinical guidelines and improved surveillance.
Enteric fever (typhoid or paratyphoid fever) in the US, principally linked to returning travelers, is typically resistant to ciprofloxacin, and with some cases also resistant to "1st-choice" antimicrobials such as ceftriaxone, CDC investigators advise treating to susceptibility whenever possible.
Christan Stager, DVM, Epidemic Intelligence Service, Centers for Disease Control and Prevention (CDC), Atlanta, GA, and colleagues conducted a cross-sectional study of antimicrobial analysis of enteric fever in the US to update CDC data that had been published before the emergence of extensively drug-resistant (XDR) Typhi strain.1 The strain, originally identified among US travelers returning from Pakistan in 2016, has subsequently been reported worldwide.
"Because resistance can evolve quickly, surveillance is important to detect emerging resistance, track trends, and guide clinical and public health decision-making," the investigators indicate.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in